[
  {
    "ts": null,
    "headline": "Eli Lilly Stock's Correction Brings Opportunity",
    "summary": "Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.",
    "url": "https://finnhub.io/api/news?id=aa212201579fa1eae1e193e7410ec4c0c10bcb8218ee8f54b6f3b6c66cadc823",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738157273,
      "headline": "Eli Lilly Stock's Correction Brings Opportunity",
      "id": 132493943,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1318526353/image_1318526353.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.",
      "url": "https://finnhub.io/api/news?id=aa212201579fa1eae1e193e7410ec4c0c10bcb8218ee8f54b6f3b6c66cadc823"
    }
  },
  {
    "ts": null,
    "headline": "Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions",
    "summary": "Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions",
    "url": "https://finnhub.io/api/news?id=f8def61af47522572cf5f66ae41408506a626ffacd78973ab3a3375991c968f6",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738134000,
      "headline": "Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions",
      "id": 132521085,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions",
      "url": "https://finnhub.io/api/news?id=f8def61af47522572cf5f66ae41408506a626ffacd78973ab3a3375991c968f6"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Appreciation Fund Q4 2024 Commentary",
    "summary": "US equities delivered positive gains in the fourth quarter and finished the 12-month period up 25% for the second year in a row. Read more here.",
    "url": "https://finnhub.io/api/news?id=8dc013d99ef520c7f5903fb80adbd52e4a90b613357ecd622efcf00be060f355",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738131360,
      "headline": "ClearBridge Appreciation Fund Q4 2024 Commentary",
      "id": 132491696,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1395549655/image_1395549655.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "US equities delivered positive gains in the fourth quarter and finished the 12-month period up 25% for the second year in a row. Read more here.",
      "url": "https://finnhub.io/api/news?id=8dc013d99ef520c7f5903fb80adbd52e4a90b613357ecd622efcf00be060f355"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Large Cap Growth ESG Strategy Q4 2024 Commentary",
    "summary": "The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=00c8dc44289fdc166f4a31d57b1af9002d4f44ce3b2eedcf50456b9cc61f0b6d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738122900,
      "headline": "ClearBridge Large Cap Growth ESG Strategy Q4 2024 Commentary",
      "id": 132491008,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1567022490/image_1567022490.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=00c8dc44289fdc166f4a31d57b1af9002d4f44ce3b2eedcf50456b9cc61f0b6d"
    }
  }
]